The Effect of Treatment Facility and Race on Survival for Signet Ring Cell Carcinoma of the Esophagus: An Analysis of the National Cancer DatabaseSeptember 2, 2020OncologyHematology
In-Depth Look at a Community- Based Population of Multiple Myeloma (MM) Patients Undergoing an in-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib in the United States (US) MM-6 StudySeptember 2, 2020OncologyMultiple MyelomaHematology
Hemolytic Anemia Secondary to Methylene Blue Administration in a G6PD Sufficient PatientSeptember 1, 2020OncologyHematology
Effective Pain Control With Very Low Dose Palliative Radiotherapy for Multiple Myeloma Patients With Osseous LesionsSeptember 1, 2020OncologyMultiple MyelomaHematology
Central Texas Veterans Health Care System’s Experiences With Hematology Oncology Clinical TrialsSeptember 1, 2020OncologyHematology
Bridging the Gap: Transforming Oncology Care Through Use of Virtual Tumor BoardsSeptember 1, 2020OncologyHematology
Analysis of Oncology Telehealth Services in Veterans Health AdministrationSeptember 1, 2020OncologyHematology
A Single Center Experience of Immune Related Adverse Events From Immune Checkpoint Inhibitors and an Attempt to Identify Populations at High RiskSeptember 1, 2020OncologyHematology
A Multi-Center Retrospective Study Evaluating Palliative Antineoplastic Therapy Administered and Medication De-escalation in Veteran Cancer Patients Toward the End-of-lifeSeptember 1, 2020OncologyHematology
FDA okays new CAR T therapy, first for mantle cell lymphomaJuly 28, 2020Lymphoma & Plasma Cell DisordersHematologyOncology
Transitioning regimen may prolong proteasome inhibitor–based therapy for MMJuly 9, 2020Multiple MyelomaHematologyOncologyLymphoma & Plasma Cell Disorders
First-in-kind anti-CD47 antibody shows promise for MDS and AML treatmentJune 19, 2020AMLLeukemia, Myelodysplasia, TransplantationHematology
